Suppr超能文献

多指标免疫组化评估可切除非小细胞肺癌中巨噬细胞表型的预后价值。

Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.

机构信息

Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway, 9019.

Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway, 9019; Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway, 9019.

出版信息

Neoplasia. 2019 Mar;21(3):282-293. doi: 10.1016/j.neo.2019.01.005. Epub 2019 Feb 10.

Abstract

Macrophages are important inflammatory cells that regulate innate and adaptive immunity in cancer. Tumor-associated macrophages (TAMs) are thought to differentiate into two main phenotypes: proinflammatory M1 and protumorigenic M2. Currently, the prognostic impact of TAMs and their M1 and M2 phenotypes is unclear in non-small cell cancer (NSCLC). The present study was set up to evaluate an approach for identifying common M1 and M2 macrophage markers and explore their clinical significance in NSCLC. Using multiplex chromogenic immunohistochemistry, tissue microarrays of 553 primary tumors and 143 paired metastatic lymph nodes of NSCLC specimens were stained to detect various putative macrophage phenotypes: M1 (HLA-DR/CD68), M2 (CD163/CD68), M2 (CD204/CD68), and pan-macrophage (CD68/CK). Correlation analyses were performed to examine the relationship between TAMs and adaptive/innate immune infiltrates. HLA-DR/CD68M1 TAM level significantly decreased from pathological stage I to III. In a compartment-specific correlation analysis, moderate to strong correlations were observed between both TAM subsets (M1 and M2) with CD3-, CD8-, CD4-, and CD45RO-positive immune cells. Survival analyses, in both stromal and intratumoral compartments, revealed that high levels of HLA-DR/CD68M1 (stroma, hazard ratio [HR] = 0.73, P = .03; intratumor, HR = 0.7, P = .04), CD204M2 (stroma, HR = 0.7, P = .02; intratumor, HR = 0.6, P = .004), and CD68 (stroma, HR = 0.69, P = .02; intratumor, HR = 0.73, P = .04) infiltration were independently associated with improved NSCLC-specific survival. In lymph nodes, the intratumoral level of HLA-DR/CD68M1 was an independent positive prognostic indicator (Cox model, HR = 0.38, P = .001). In conclusion, high levels of M1, CD204M2, and CD68 macrophages are independent prognosticators of prolonged survival in NSCLC.

摘要

巨噬细胞是调节癌症中先天和适应性免疫的重要炎症细胞。肿瘤相关巨噬细胞(TAMs)被认为可分化为两种主要表型:促炎 M1 和促肿瘤发生的 M2。目前,TAMs 及其 M1 和 M2 表型在非小细胞肺癌(NSCLC)中的预后影响尚不清楚。本研究旨在评估一种鉴定常见 M1 和 M2 巨噬细胞标志物的方法,并探讨其在 NSCLC 中的临床意义。使用多重显色免疫组织化学方法,对 553 例原发性肿瘤和 143 例 NSCLC 标本配对转移淋巴结的组织微阵列进行染色,以检测各种潜在的巨噬细胞表型:M1(HLA-DR/CD68)、M2(CD163/CD68)、M2(CD204/CD68)和泛巨噬细胞(CD68/CK)。进行相关性分析以检查 TAMs 与适应性/先天免疫浸润之间的关系。HLA-DR/CD68M1 TAM 水平从病理分期 I 到 III 显著降低。在特定于隔室的相关性分析中,M1 和 M2 两个 TAM 亚群与 CD3、CD8、CD4 和 CD45RO 阳性免疫细胞之间观察到中度至强相关性。在基质和肿瘤内隔室的生存分析中,高水平的 HLA-DR/CD68M1(基质,风险比 [HR] = 0.73,P =.03;肿瘤内,HR = 0.7,P =.04)、CD204M2(基质,HR = 0.7,P =.02;肿瘤内,HR = 0.6,P =.004)和 CD68(基质,HR = 0.69,P =.02;肿瘤内,HR = 0.73,P =.04)浸润与 NSCLC 特异性生存的改善独立相关。在淋巴结中,肿瘤内 HLA-DR/CD68M1 水平是独立的阳性预后指标(Cox 模型,HR = 0.38,P =.001)。总之,高水平的 M1、CD204M2 和 CD68 巨噬细胞是 NSCLC 患者生存延长的独立预后因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验